TY - JOUR
TI - Myelin-oligodendrocyte glycoprotein antibody-associated disease
AU - Marignier, R.
AU - Hacohen, Y.
AU - Cobo-Calvo, A.
AU - Pröbstel, A.-K.
AU - Aktas, O.
AU - Alexopoulos, H.
AU - Amato, M.-P.
AU - Asgari, N.
AU - Banwell, B.
AU - Bennett, J.
AU - Brilot, F.
AU - Capobianco, M.
AU - Chitnis, T.
AU - Ciccarelli, O.
AU - Deiva, K.
AU - De Sèze, J.
AU - Fujihara, K.
AU - Jacob, A.
AU - Kim, H.J.
AU - Kleiter, I.
AU - Lassmann, H.
AU - Leite, M.-I.
AU - Linington, C.
AU - Meinl, E.
AU - Palace, J.
AU - Paul, F.
AU - Petzold, A.
AU - Pittock, S.
AU - Reindl, M.
AU - Sato, D.K.
AU - Selmaj, K.
AU - Siva, A.
AU - Stankoff, B.
AU - Tintore, M.
AU - Traboulsee, A.
AU - Waters, P.
AU - Waubant, E.
AU - Weinshenker, B.
AU - Derfuss, T.
AU - Vukusic, S.
AU - Hemmer, B.
JO - The Lancet Neurology
PY - 2021
VL - 20
TODO - 9
SP - 762-772
PB - The Lancet Publishing Group
SN - null
TODO - 10.1016/S1474-4422(21)00218-0
TODO - corticosteroid;  immunoglobulin;  methylprednisolone;  autoantibody;  biological marker;  immunologic factor;  MOG protein, human;  myelin oligodendrocyte glycoprotein, adult;  antibody detection;  autoimmune disease;  child;  clinical feature;  clinical trial (topic);  human;  long term care;  myelin oligodendrocyte glycoprotein antibody associated disease;  myelin oligodendrocyte glycoprotein antibody associated disease;  neuroimaging;  nonhuman;  nuclear magnetic resonance imaging;  optical coherence tomography;  relapse;  Review;  adolescent;  blood;  demyelinating disease;  immunology;  middle aged;  pathology;  pathophysiology;  young adult, Adolescent;  Adult;  Autoantibodies;  Biomarkers;  Child;  Demyelinating Autoimmune Diseases, CNS;  Humans;  Immunologic Factors;  Middle Aged;  Myelin-Oligodendrocyte Glycoprotein;  Young Adult
TODO - Myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified autoimmune disorder that presents in both adults and children as CNS demyelination. Although there are clinical phenotypic overlaps between MOGAD, multiple sclerosis, and aquaporin-4 antibody-associated neuromyelitis optica spectrum disorder (NMOSD) cumulative biological, clinical, and pathological evidence discriminates between these conditions. Patients should not be diagnosed with multiple sclerosis or NMOSD if they have anti-MOG antibodies in their serum. However, many questions related to the clinical characterisation of MOGAD and pathogenetic role of MOG antibodies are still unanswered. Furthermore, therapy is mainly based on standard protocols for aquaporin-4 antibody-associated NMOSD and multiple sclerosis, and more evidence is needed regarding how and when to treat patients with MOGAD. © 2021 Elsevier Ltd
ER -